marketcaparena
Search

    ANAB

    ANAPTYSBIO, INC

    Company overview

    Market capitalization
    —
    Employees
    104
    Latest publication
    2026-09-29
    About ANAPTYSBIO, INC

    AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20212021-06-30 · USDQ4 20202020-12-31 · USDQ3 20202020-09-30 · USDQ2 20202020-06-30 · USDQ3 20192019-09-30 · USD
    Total Revenue25,556,000USD108,249,000USD76,320,000USD30,027,000USD60,000,000USD0USD0USD0USD
    Cost Of Revenue610,000USD-107,988,000USD31,407,000USD25,314,000USD21,567,000USD19,542,000USD17,948,000USD29,931,000USD
    Gross Profit24,946,000USD216,237,000USD44,913,000USD4,713,000USD38,433,000USD-19,542,000USD-17,948,000USD-29,931,000USD
    Research Development33,861,000USD25,559,000USD31,407,000USD25,314,000USD21,567,000USD19,542,000USD17,948,000USD29,931,000USD
    Selling General Administrative26,202,000USD15,789,000USD10,209,000USD5,246,000USD5,088,000USD4,794,000USD4,687,000USD3,814,000USD
    Total Operating Expenses59,583,000USD149,336,000USD10,209,000USD5,246,000USD5,088,000USD4,794,000USD4,687,000USD3,814,000USD
    Operating Income-34,637,000USD66,901,000USD34,704,000USD-533,000USD33,345,000USD-24,336,000USD-22,635,000USD-33,745,000USD
    Interest Income2,653,000USD2,508,000USD2,924,000USD104,000USD376,000USD625,000USD1,061,000USD2,757,000USD
    Interest Expense20,859,000USD19,711,000USD22,515,000USD104,000USD376,000USD625,000USD1,061,000USD240,000USD
    Net Interest Income-18,206,000USD-17,203,000USD-19,591,000USD104,000USD376,000USD625,000USD1,061,000USD2,517,000USD
    Income Before Tax-52,844,000USD49,695,000USD15,113,000USD-429,000USD33,646,000USD-23,767,000USD-21,548,000USD-31,084,000USD
    Income Tax Expense40,000USD81,000USD——-75,000USD-56,000USD26,000USD-51,000USD
    Tax Provision40,000USD81,000USD0USD—0USD0USD0USD-51,000USD
    Net Income-52,884,000USD49,614,000USD15,113,000USD-429,000USD33,646,000USD-23,767,000USD-21,548,000USD-31,033,000USD
    Net Income From Continuing Ops-52,884,000USD49,614,000USD15,113,000USD-429,000USD33,646,000USD-23,767,000USD-21,548,000USD-31,033,000USD
    Ebit-31,985,000USD69,406,000USD37,628,000USD-429,000USD33,646,000USD-23,767,000USD-21,548,000USD-30,844,000USD
    Ebitda-31,375,000USD70,012,000USD38,238,000USD482,000USD33,790,000USD-23,629,000USD-21,411,000USD-30,709,000USD
    Depreciation And Amortization610,000USD606,000USD610,000USD911,000USD144,000USD138,000USD137,000USD135,000USD
    Reconciled Depreciation610,000USD606,000USD610,000USD911,000USD144,000USD138,000USD137,000USD135,000USD
    Total Other Income Expense Net-18,207,000USD-17,206,000USD-19,591,000USD104,000USD301,000USD569,000USD1,087,000USD2,661,000USD
    Other Operating Expenses—41,348,000USD——————
    Unclassified Operating Expenses—66,640,000USD-31,407,000USD-25,314,000USD-21,567,000USD-19,542,000USD-17,948,000USD-29,931,000USD
    Net Income Applicable To Common Shares———-429,000USD33,646,000USD-23,767,000USD-21,548,000USD-31,033,000USD
    Non Operating Income Net Other————3,542,000USD-56,000USD26,000USD144,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USD
    Total Revenue234,603,000USD
    Cost Of Revenue2,423,000USD
    Gross Profit232,180,000USD
    Research Development135,970,000USD
    Selling General Administrative50,737,000USD
    Unclassified Operating Expenses-2,423,000USD
    Total Operating Expenses184,284,000USD
    Operating Income47,896,000USD
    Interest Income13,499,000USD
    Interest Expense79,893,000USD
    Net Interest Income-66,394,000USD
    Income Before Tax-13,068,000USD
    Income Tax Expense164,000USD
    Tax Provision164,000USD
    Net Income-13,232,000USD
    Net Income From Continuing Ops-13,232,000USD
    Ebit66,825,000USD
    Ebitda69,248,000USD
    Depreciation And Amortization2,423,000USD
    Reconciled Depreciation2,423,000USD
    Total Other Income Expense Net-60,964,000USD
    SourceLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Total Assets329,684,000USD364,395,000USD353,098,000USD335,250,000USD422,053,000USD483,834,000USD493,418,000USD427,376,000USD
    Other Current Assets3,907,000USD4,762,000USD6,009,000USD4,778,000USD5,292,000USD5,738,000USD6,369,000USD7,539,000USD
    Total Liab316,937,000USD327,185,000USD382,514,000USD379,983,000USD388,032,000USD412,966,000USD409,051,000USD417,497,000USD
    Total Stockholder Equity12,747,000USD37,210,000USD-29,416,000USD-44,733,000USD34,021,000USD70,868,000USD84,367,000USD9,879,000USD
    Other Current Liab32,065,000USD32,674,000USD33,171,000USD30,197,000USD32,408,000USD39,501,000USD38,401,000USD33,680,000USD
    Common Stock29,000USD28,000USD28,000USD28,000USD30,000USD30,000USD30,000USD27,000USD
    Capital Stock29,000USD28,000USD28,000USD28,000USD30,000USD30,000USD30,000USD27,000USD
    Retained Earnings-825,443,000USD-772,559,000USD-822,173,000USD-837,286,000USD-798,656,000USD-759,327,000USD-737,543,000USD-704,692,000USD
    Cash248,469,000USD238,196,000USD109,833,000USD44,298,000USD98,637,000USD123,080,000USD191,581,000USD71,821,000USD
    Cash And Short Term Investments286,455,000USD311,638,000USD248,956,000USD265,710,000USD339,936,000USD385,373,000USD430,117,000USD350,804,000USD
    Total Current Assets316,109,000USD350,250,000USD330,650,000USD291,906,000USD363,112,000USD431,876,000USD448,681,000USD367,350,000USD
    Total Current Liabilities41,702,000USD38,625,000USD38,104,000USD35,527,000USD44,037,000USD45,428,000USD43,880,000USD40,420,000USD
    Net Debt28,886,000USD52,444,000USD236,617,000USD-29,202,000USD-83,062,000USD-107,043,000USD-175,087,000USD-54,875,000USD
    Short Term Debt2,120,000USD2,080,000USD2,040,000USD2,001,000USD1,962,000USD1,925,000USD1,887,000USD1,850,000USD
    Short Long Term Debt Total277,355,000USD290,640,000USD346,450,000USD15,096,000USD15,575,000USD16,037,000USD16,494,000USD16,946,000USD
    Short Term Investments37,986,000USD73,442,000USD139,123,000USD221,412,000USD241,299,000USD262,293,000USD238,536,000USD278,983,000USD
    Net Receivables25,747,000USD33,850,000USD75,685,000USD21,418,000USD17,884,000USD40,765,000USD12,195,000USD9,007,000USD
    Accounts Payable7,517,000USD3,871,000USD2,893,000USD3,329,000USD6,123,000USD4,002,000USD3,592,000USD4,890,000USD
    Property Plant Equipment Net13,319,000USD13,889,000USD14,494,000USD15,092,000USD15,664,000USD16,232,000USD16,567,000USD17,124,000USD
    Property Plant Equipment Gross20,588,000USD21,028,000USD21,503,000USD21,967,000USD22,397,000USD22,831,000USD23,037,000USD23,637,000USD
    Accumulated Other Comprehensive Income-146,000USD-24,000USD47,000USD-6,000USD161,000USD305,000USD759,000USD-415,000USD
    Common Stock Shares Outstanding28,691,000shares31,343,000shares29,018,000shares28,810,000shares30,644,000shares30,448,000shares28,893,000shares27,356,000shares
    Non Current Assets Total13,575,000USD14,145,000USD22,448,000USD43,344,000USD58,941,000USD51,958,000USD44,737,000USD60,026,000USD
    Non Current Liabilities Total275,235,000USD288,560,000USD344,410,000USD344,456,000USD343,995,000USD367,538,000USD365,171,000USD377,077,000USD
    Non Current Liabilities Other263,742,000USD276,528,000USD331,844,000USD331,361,000USD330,382,000USD353,426,000USD350,564,000USD361,981,000USD
    Non Currrent Assets Other256,000USD256,000USD256,000USD256,000USD256,000USD256,000USD256,000USD256,000USD
    Net Working Capital274,407,000USD311,625,000USD292,546,000USD256,379,000USD319,075,000USD386,448,000USD404,801,000USD326,930,000USD
    Unclassified Non Current Liabilities11,493,000USD12,032,000USD12,566,000USD13,095,000USD13,613,000USD14,112,000USD14,607,000USD15,096,000USD
    Unclassified Equity838,278,000USD809,737,000USD792,654,000USD792,503,000USD832,456,000USD829,830,000USD821,091,000USD714,932,000USD
    Long Term Investments—0USD7,698,000USD27,996,000USD43,021,000USD35,470,000USD27,914,000USD42,646,000USD
    Current Deferred Revenue————3,544,000USD———
    Inventory——————-12,195,000USD1USD
    Other Assets———————1USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets364,395,000USD483,834,000USD452,389,000USD610,383,000USD643,070,000USD416,552,000USD435,197,000USD508,997,000USD
    Other Current Assets4,762,000USD5,738,000USD9,080,000USD4,545,000USD4,903,000USD2,908,000USD3,506,000USD6,960,000USD
    Total Liab327,185,000USD412,966,000USD364,286,000USD348,280,000USD286,642,000USD19,821,000USD30,189,000USD22,632,000USD
    Total Stockholder Equity37,210,000USD70,868,000USD88,103,000USD262,103,000USD356,428,000USD396,731,000USD405,008,000USD486,365,000USD
    Other Current Liab32,674,000USD39,501,000USD30,967,000USD21,633,000USD12,853,000USD15,262,000USD11,052,000USD8,761,000USD
    Common Stock28,000USD30,000USD27,000USD29,000USD28,000USD27,000USD27,000USD27,000USD
    Capital Stock28,000USD30,000USD27,000USD29,000USD28,000USD27,000USD27,000USD27,000USD
    Retained Earnings-772,559,000USD-759,327,000USD-614,096,000USD-450,477,000USD-321,753,000USD-263,957,000USD-244,026,000USD-146,690,000USD
    Cash238,196,000USD123,080,000USD35,965,000USD71,308,000USD495,729,000USD250,456,000USD171,017,000USD113,596,000USD
    Cash And Short Term Investments311,638,000USD385,373,000USD390,904,000USD441,241,000USD548,097,000USD393,653,000USD374,227,000USD427,082,000USD
    Total Current Assets350,250,000USD431,876,000USD406,835,000USD447,205,000USD553,876,000USD396,561,000USD377,733,000USD434,216,000USD
    Total Current Liabilities38,625,000USD45,428,000USD37,442,000USD26,054,000USD16,099,000USD19,821,000USD29,535,000USD21,836,000USD
    Net Debt-224,084,000USD246,383,000USD-18,151,000USD-51,858,000USD-474,774,000USD-250,114,000USD-168,117,000USD-105,339,000USD
    Short Term Debt2,080,000USD1,925,000USD1,777,000USD1,637,000USD1,505,000USD342,000USD2,246,000USD7,632,000USD
    Short Long Term Debt Total14,112,000USD369,463,000USD17,814,000USD19,450,000USD20,955,000USD342,000USD2,900,000USD8,257,000USD
    Long Term Investments0USD35,470,000USD27,026,000USD142,935,000USD67,097,000USD17,546,000USD54,305,000USD73,128,000USD
    Short Term Investments73,442,000USD262,293,000USD354,939,000USD369,933,000USD52,368,000USD143,197,000USD203,210,000USD313,486,000USD
    Net Receivables33,850,000USD40,765,000USD6,851,000USD1,419,000USD876,000USD0USD—174,000USD
    Accounts Payable3,871,000USD4,002,000USD4,698,000USD2,784,000USD1,741,000USD4,217,000USD16,237,000USD5,443,000USD
    Property Plant Equipment Net13,889,000USD16,232,000USD18,272,000USD19,987,000USD21,841,000USD2,127,000USD1,618,000USD1,445,000USD
    Property Plant Equipment Gross21,028,000USD22,831,000USD24,490,000USD19,987,000USD21,841,000USD1,783,000USD1,618,000USD1,445,000USD
    Accumulated Other Comprehensive Income-24,000USD305,000USD-797,000USD-5,246,000USD-422,000USD-4,000USD338,000USD-223,000USD
    Common Stock Shares Outstanding31,343,000shares28,382,000shares26,924,000shares28,165,000shares27,431,000shares27,302,000shares27,059,000shares24,673,000shares
    Non Current Assets Total14,145,000USD51,958,000USD45,554,000USD163,178,000USD89,194,000USD19,991,000USD57,464,000USD74,781,000USD
    Non Current Liabilities Total288,560,000USD367,538,000USD326,844,000USD322,226,000USD270,543,000USD4,559,000USD654,000USD796,000USD
    Non Current Liabilities Other276,528,000USD353,426,000USD310,807,000USD304,413,000USD251,093,000USD—654,000USD171,000USD
    Non Currrent Assets Other256,000USD256,000USD256,000USD256,000USD256,000USD318,000USD1,541,000USD208,000USD
    Net Working Capital311,625,000USD386,448,000USD369,393,000USD421,151,000USD537,777,000USD376,740,000USD348,198,000USD412,380,000USD
    Unclassified Non Current Liabilities12,032,000USD14,112,000USD16,037,000USD-286,600,000USD-231,643,000USD4,559,000USD——
    Unclassified Equity809,737,000USD829,830,000USD702,942,000USD717,768,000USD678,547,000USD660,638,000USD648,642,000USD633,224,000USD
    Inventory——1USD1USD1USD———
    Other Liab———304,413,000USD251,093,000USD—654,000USD796,000USD
    Other Assets———256,000USD256,000USD18,208,000USD139,000USD208,000USD
    Net Tangible Assets———584,329,000USD626,971,000USD396,731,000USD405,008,000USD486,365,000USD
    Unclassified Non Current Assets—————-18,208,000USD——
    Current Deferred Revenue——————10,181,000USD8,703,000USD
    Short Long Term Debt——————1,375,000USD7,574,000USD
    Unclassified Current Liabilities——————-11,556,000USD-16,277,000USD
    Long Term Debt———————625,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income-52,884,000USD49,614,000USD15,113,000USD-38,630,000USD-39,329,000USD-21,784,000USD-32,851,000USD-46,660,000USD
    Depreciation610,000USD606,000USD610,000USD601,000USD606,000USD601,000USD596,000USD595,000USD
    Stock Based Compensation14,218,000USD8,506,000USD9,157,000USD9,239,000USD9,170,000USD8,184,000USD8,189,000USD7,544,000USD
    Other Non Cash Items19,845,000USD19,371,000USD21,385,000USD18,009,000USD16,394,000USD15,102,000USD15,297,000USD8,476,000USD
    Change To Account Receivables8,103,000USD41,835,000USD-54,267,000USD-3,534,000USD22,881,000USD-28,570,000USD2,156,000USD-1,918,000USD
    Change In Working Capital-7,708,000USD19,900,000USD-73,621,000USD-29,463,000USD2,459,000USD-68,775,000USD-1,321,000USD8,723,000USD
    Total Cash From Operating Activities-25,919,000USD97,997,000USD-27,356,000USD-40,244,000USD-10,700,000USD-66,672,000USD-10,090,000USD-21,322,000USD
    Capital Expenditures-17,000USD-1,000USD-12,000USD-39,000USD-35,000USD-263,000USD-35,000USD-33,000USD
    Free Cash Flow-25,936,000USD97,996,000USD-27,368,000USD-40,283,000USD-10,735,000USD-66,935,000USD-10,125,000USD-21,355,000USD
    Investments35,000,000USD73,501,000USD103,282,000USD36,403,000USD14,847,000USD-29,396,000USD58,620,000USD-2,442,000USD
    Total Cashflows From Investing Activities34,983,000USD73,500,000USD103,282,000USD36,403,000USD14,847,000USD-29,396,000USD58,620,000USD-2,442,000USD
    Total Cash From Financing Activities1,209,000USD-43,134,000USD-10,391,000USD-50,498,000USD-28,590,000USD27,567,000USD71,230,000USD41,890,000USD
    Sale Purchase Of Stock0USD-3,384,000USD-9,720,000USD-51,098,000USD-4,424,000USD-456,000USD0USD0USD
    Issuance Of Capital Stock14,021,000USD12,212,000USD336,000USD1,423,000USD290,000USD555,000USD98,497,000USD979,000USD
    Change In Cash10,273,000USD128,363,000USD65,535,000USD-54,339,000USD-24,443,000USD-68,501,000USD119,760,000USD18,126,000USD
    Begin Period Cash Flow238,196,000USD109,833,000USD44,298,000USD98,637,000USD123,080,000USD191,581,000USD71,821,000USD53,695,000USD
    End Period Cash Flow248,469,000USD238,196,000USD109,833,000USD44,298,000USD98,637,000USD123,080,000USD191,581,000USD71,821,000USD
    Other Cashflows From Financing Activities1,209,000USD-43,134,000USD-10,391,000USD—-24,456,000USD27,468,000USD-370,000USD40,911,000USD
    Unclassified Financing Cash Flow—3,384,000USD9,720,000USD———71,600,000USD—
    Other Cashflows From Investing Activities———————-2,409,000USD
    Unclassified Investing Cash Flow———————2,442,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USDFY 20172017-12-31 · USD
    Net Income-145,231,000USD-163,619,000USD-128,724,000USD-57,796,000USD-19,931,000USD-97,336,000USD-61,656,000USD-30,070,000USD
    Depreciation2,397,000USD2,376,000USD2,335,000USD2,090,000USD559,000USD514,000USD315,000USD183,000USD
    Stock Based Compensation34,048,000USD33,205,000USD27,356,000USD15,347,000USD11,499,000USD12,411,000USD9,961,000USD4,378,000USD
    Other Non Cash Items39,774,000USD7,562,000USD18,601,000USD1,928,000USD487,000USD-1,957,000USD646,000USD619,000USD
    Change To Account Receivables-33,914,000USD-5,432,000USD-543,000USD-876,000USD-876,000USD174,000USD1,427,000USD1,225,000USD
    Change In Working Capital-66,325,000USD-324,000USD6,839,000USD-7,489,000USD-6,771,000USD16,851,000USD3,461,000USD4,075,000USD
    Total Cash From Operating Activities-135,337,000USD-120,800,000USD-73,593,000USD-45,920,000USD-14,157,000USD-69,517,000USD-48,506,000USD-19,438,000USD
    Capital Expenditures-358,000USD-807,000USD-358,000USD-1,366,000USD-569,000USD-805,000USD-1,063,000USD-290,000USD
    Free Cash Flow-135,695,000USD-121,607,000USD-73,951,000USD-47,286,000USD-14,726,000USD-70,322,000USD-49,569,000USD-19,728,000USD
    Investments95,398,000USD117,073,000USD-394,487,000USD40,186,000USD95,044,000USD132,236,000USD-141,388,000USD-242,768,000USD
    Total Cashflows From Investing Activities95,398,000USD144,754,000USD-394,845,000USD38,835,000USD94,475,000USD131,431,000USD-142,451,000USD-243,058,000USD
    Total Cash From Financing Activities127,054,000USD-59,297,000USD44,017,000USD252,298,000USD-879,000USD-4,493,000USD223,364,000USD292,453,000USD
    Sale Purchase Of Stock-456,000USD-50,000,000USD11,827,000USD2,553,000USD496,000USD3,007,000USD230,270,000USD294,052,000USD
    Issuance Of Capital Stock100,842,000USD5,627,000USD11,827,000USD2,553,000USD496,000USD0USD227,476,000USD—
    Change In Cash87,115,000USD-35,343,000USD-424,421,000USD245,213,000USD79,439,000USD57,421,000USD32,407,000USD29,957,000USD
    Begin Period Cash Flow35,965,000USD71,308,000USD495,729,000USD250,516,000USD171,017,000USD113,596,000USD81,249,000USD51,292,000USD
    End Period Cash Flow123,080,000USD35,965,000USD71,308,000USD495,729,000USD250,456,000USD171,017,000USD113,656,000USD81,249,000USD
    Other Cashflows From Financing Activities-8,099,000USD-43,000USD32,190,000USD249,745,000USD94,475,000USD-4,493,000USD2,763,000USD-84,000USD
    Unclassified Financing Cash Flow135,609,000USD2,472,000USD——-94,475,000USD4,493,000USD-2,794,000USD5,360,000USD
    Change To Inventory—5,108,000USD———-174,000USD—-237,974,000USD
    Dividends Paid—-11,726,000USD—————0USD
    Unclassified Investing Cash Flow—28,488,000USD394,487,000USD—194,927,000USD251,815,000USD347,537,000USD290,905,000USD
    Change To Liabilities——9,700,000USD-4,740,000USD-8,877,000USD14,499,000USD7,222,000USD2,218,000USD
    Net Borrowings——0USD0USD-1,375,000USD-7,500,000USD-6,875,000USD-6,875,000USD
    Cash And Cash Equivalents Changes——-424,421,000USD245,213,000USD79,439,000USD57,421,000USD32,407,000USD29,957,000USD
    Other Cashflows From Investing Activities——-394,487,000USD15,000USD-194,927,000USD-251,815,000USD-347,537,000USD-290,905,000USD
    Unclassified Operating Cash Flow——————-1,233,000USD1,377,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q1 2026Quarterly · 2026-03-31SegmentBiopharma Company0USD0001193125-26-219515
    Q1 2026Quarterly · 2026-03-31SegmentRoyalty Management Company25,556,000USD0001193125-26-219515
    FY 2025Yearly · 2025-12-31SegmentBiopharma Company0USD0001193125-26-088290
    FY 2025Yearly · 2025-12-31SegmentRoyalty Management Company234,603,000USD0001193125-26-088290
    Q1 2025Quarterly · 2025-03-31SegmentBiopharma Company0USD0001193125-26-219515
    Q1 2025Quarterly · 2025-03-31SegmentRoyalty Management Company27,771,000USD0001193125-26-219515
    FY 2024Yearly · 2024-12-31SegmentBiopharma Company0USD0001193125-26-088290
    FY 2024Yearly · 2024-12-31SegmentRoyalty Management Company91,280,000USD0001193125-26-088290
    FY 2023Yearly · 2023-12-31SegmentBiopharma Company0USD0001193125-26-088290
    FY 2023Yearly · 2023-12-31SegmentRoyalty Management Company17,157,000USD0001193125-26-088290
    Q4 2021Quarterly · 2021-12-31ProductAnaptys Bio Generated Anti PD1JEMPERLIDostarlimab0USDLegacy provider
    Q4 2021Quarterly · 2021-12-31ProductZejula And Anaptys Bio Generated JEMPERLI1,100,000USDLegacy provider
    FY 2021Yearly · 2021-12-31ProductAnaptys Bio Generated Anti PD1JEMPERLIDostarlimab60,000,000USD0001370053-23-000020
    FY 2021Yearly · 2021-12-31ProductZejula And Anaptys Bio Generated JEMPERLI3,200,000USD0001370053-23-000020
    Q3 2021Quarterly · 2021-09-30ProductAnaptys Bio Generated Anti PD1JEMPERLIDostarlimab20,000,000USD0001370053-22-000066
    Q3 2021Quarterly · 2021-09-30ProductZejula And Anaptys Bio Generated JEMPERLI900,000USD0001370053-22-000066
    Q2 2021Quarterly · 2021-06-30ProductAnaptys Bio Generated Anti PD1JEMPERLIDostarlimab30,000,000USD0001370053-22-000043
    Q2 2021Quarterly · 2021-06-30ProductZejula And Anaptys Bio Generated JEMPERLI0USD0001370053-22-000043
    Q1 2021Quarterly · 2021-03-31ProductAnaptys Bio Generated Anti PD1JEMPERLIDostarlimab10,000,000USD0001370053-22-000032
    Q1 2021Quarterly · 2021-03-31ProductZejula And Anaptys Bio Generated JEMPERLI1,200,000USD0001370053-22-000032

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.